B · Normal
[Kangfang Biologics rises in Hong Kong. Its Evosi single drug has a longer overall survival than Merck’s competing products in trials] On September 14th, Kangfang Biologics rose 5.8% at the beginning of the session, and then narrowed the gains. The company previously announced that compared with Merck & Co.'s pembrolizumab, its oncology immunotherapy drug Ivorosid significantly extended the median overall survival (OS) to 30.8 months, compared with 22.6 months for the former.
Comments